Compound hub · Retatrutide
Retatrutide pharmacokinetics: what is the half-life?
A Phase 1 study of 45 healthy adults in Singapore measured retatrutide's half-life. The half-life is the time for the blood level to fall by half. The group averages ran from 134 to 165 hours, which is about 5.6 to 6.9 days. This result comes from one small, mostly male group. It does not describe other people or other retatrutide material (Coskun et al., Cell Metabolism, 2022). A Phase 1b study of 72 adults with type 2 diabetes reports a half-life. It is approximately six days. That holds for this small early-phase trial only (Urva et al., The Lancet, 2022).
Form Labs materials are research reference materials, not the approved medicines; no Form Labs product is approved for human or veterinary use.
The body clears different substances at different speeds.
Published measurements of retatrutide run on a different clock. That is why its PK gets a page of its own. PK is what the body does to the molecule over time. This page is part of the retatrutide hub. It lays out the published human measurements of arrival, peak and clearance. It also says plainly what has not been measured at all.
- Guidethe retatrutide hubRetatrutide research hub: what the compound is, which receptor systems the literature maps it to, what the published trials measured, and how it compares with approved medicines.
Key facts
| Common name | retatrutide |
|---|---|
| Research code | LY3437943 |
| Developer | Eli Lilly |
| Structure | 39-amino-acid peptide, GIP backbone |
| Half-life extension | C20 fatty diacid attached via a linker at Lys17 |
| Reported half-life | About 6 days in a Phase 1b study of 72 adults with type 2 diabetes. It was a small early-phase trial funded by the developer, so it describes that group only (Urva et al., The Lancet, 2022) |
| Half-life range measured | 134–165 h (about 5.6–6.9 days). These are geometric means for six groups in one Phase 1 study of 45 healthy adults. It was a small single-exposure study, so it describes those adults only (Coskun et al., Cell Metabolism, 2022) |
| Time to peak concentration | Group medians were 12–72 h after a single exposure in a Phase 1 study of 45 healthy adults. It was a small study, so it describes those adults only (Coskun et al., Cell Metabolism, 2022) |
| Dose proportionality | Exposure rose nearly in step with the dose across six groups in a Phase 1 study of 45 healthy adults. That holds within the range studied only (Coskun et al., Cell Metabolism, 2022). A Phase 1b study of 72 adults with type 2 diabetes reported the same, in a small early-phase trial (Urva et al., The Lancet, 2022) |
| Between-person variability | CV 13–34% (AUC) and 10–37% (Cmax) across six groups in one Phase 1 study of 45 healthy adults. It was a small study, so it describes those adults only (Coskun et al., Cell Metabolism, 2022) |
| Single-exposure PK trial | NCT03841630 (healthy adults, Singapore, 2019) |
| Repeated-exposure PK trial | NCT04143802 (type 2 diabetes, United States, 2019–2020) |
| Human ADME study | Not reported in the Coskun 2022, Urva 2022 and Carneiro 2026 papers checked on 14 October 2026 |
| Kidney and liver impairment PK trials | NCT05611957 (29 participants, completed 5 September 2023) and NCT05916560 (43 participants, completed 2 March 2025). No results were posted as of 14 October 2026 |
| Trial phase as of 2026 | Phase 3 |
- SourceNCT03841630
- SourceNCT04143802
- SourceNCT05611957
- SourceNCT05916560
What is retatrutide's half-life?
A Phase 1 study of 45 healthy adults in Singapore measured retatrutide's half-life. The group averages ran from 134 to 165 hours, about 5.6 to 6.9 days. This holds for that small, mostly male group only (Coskun et al., Cell Metabolism, 2022). A half-life is the time for the amount in the blood to fall by half. A Phase 1b study of 72 adults with type 2 diabetes reports a half-life. It is approximately six days. The developer funded that early-phase study (Urva et al., The Lancet, 2022). The retatrutide research guide covers what the compound is. This page covers what the body does to it.
A half-life is a clock, not a wall. After one half-life, about half of the measured amount is still in the blood. After two, about a quarter is. In the Phase 1b study, the half-life was near six days. That meant the measured level fell by half about once a week in that group. It is a small early-phase result. It does not describe other people (Urva et al., The Lancet, 2022).
The summary hides real spread. In the small Phase 1 study in Singapore, single half-lives ran from 104 to 225 hours. Those are the lowest and highest values in the trial's half-life column. That span is wider than the 134-to-165-hour band of group averages. So one person's value could sit well away from a group figure (Coskun et al., Cell Metabolism, 2022).
GuideThe retatrutide research guideA plain-English guide to LY3437943: what it is, the three receptor systems, what each trial phase found, and where the evidence stops.
Evidence limits
What has not been published about retatrutide's pharmacokinetics?
Three papers leave three kinds of retatrutide evidence unreported. They are Coskun 2022, Urva 2022 and Carneiro 2026, checked for this page on 14 October 2026. First, they report no human ADME study. That is no map of the compound's metabolites, which are the breakdown products the body makes. It is no count of how much leaves in urine or faeces. It is no work on which CYP enzymes take part. CYP enzymes are the liver's main drug-processing family. Second, trials in kidney impairment and liver impairment are registered and completed. They have no results posted (ClinicalTrials.gov NCT05611957 and NCT05916560, checked 14 October 2026). Third, the papers report no population PK or exposure-response analysis that pools data across trials. The half-life, peak-time and proportionality figures on this page come from two Phase 1 studies. These are Coskun et al., 2022 and Urva et al., 2022.
The same three papers contain no Phase 3 PK tables. They report no head-to-head PK comparison of retatrutide with semaglutide or tirzepatide. How retatrutide, Mounjaro, and Ozempic differ compares separate published records. It does not compare one shared measurement. This page gives no build-up ratio or time-to-steady-state figure. We could not retrieve the full PK table in Urva et al. (The Lancet, 2022) on 14 October 2026.
The people behind the numbers matter as much as the numbers. The Singapore study enrolled 45 healthy adults. Of them, 42 were male and 44 were Asian. So its results may not fit women or other groups (Coskun et al., Cell Metabolism, 2022). The weight and blood-sugar changes in these same papers are pharmacodynamic outcomes. That means what the compound did in the body. They are not PK.
- SourceNCT05611957
- SourceNCT05916560
- GuideHow retatrutide, Mounjaro, and Ozempic differRetatrutide, Mounjaro, and Ozempic compared by molecule, receptor systems, and approval status. Research material is not a medicine.
What does pharmacokinetics actually measure?
Pharmacokinetics (PK) is the study of what the body does to a compound over time. It asks how fast the compound reaches the blood and how high it climbs. It asks how far it spreads. It also asks how long it takes to leave. Four measures carry most of the answer. Cmax is the highest level reached. Tmax is how long it took to get there. The t½ is the half-life. AUC is total exposure, the area under the whole level-versus-time curve. The early measurements discussed here come from two early-phase trials. NCT03841630 was a single-exposure study in 45 healthy adults in Singapore (Coskun et al., Cell Metabolism, 2022). NCT04143802 was a repeated-exposure study in 72 adults with type 2 diabetes (Urva et al., The Lancet, 2022).
PK has a mirror field, and you will meet the difference again. PK is what the body does to the compound. Pharmacodynamics is what the compound does in the body. The gastric-emptying paper is a clean example. Urva et al. examined gastric emptying as a pharmacodynamic endpoint (Diabetes, Obesity and Metabolism, 2023).
The two Phase 1 trials behind the half-life, peak-time and proportionality figures ran in different places and years. One ran from March to July 2019 in Singapore. The other ran from December 2019 to December 2020 in the United States. How long retatrutide has been studied lays out that full timeline. It also shows where these two early studies sit in it.
- SourceNCT03841630
- SourceNCT04143802
- GuideHow long retatrutide has been studiedRetatrutide's research record from the first dated human enrollment in December 2019 to Phase 3 in 2026. Research material is not a medicine.
How long does retatrutide take to reach peak levels in the blood?
In the Phase 1 study of 45 healthy adults, the median time to peak blood level after a single exposure was 72 hours in the lowest group. It was 12 hours in the second-highest group. So group medians ran from 12 to 72 hours, with wide spreads between people at every level. The result describes that small study only (Coskun et al., Cell Metabolism, 2022).
The medians hide wide spreads. In the lowest group, the median time to peak was 72.0 hours, with some people out to 119.8 hours. In the second-highest group, the earliest single peak came at 4 hours, against a median of 12.0. So in that small study a median does not describe any one participant (Coskun et al., Cell Metabolism, 2022). The table below lists what each study enrolled and measured.
How long does retatrutide take to kick in, according to studies?
In the Phase 1 study of 45 healthy adults, the group-median time to peak blood level after a single exposure was 12 to 72 hours. That is one small study. It measures a blood peak, not the start of an effect (Coskun et al., Cell Metabolism, 2022). None of these papers says when retatrutide starts to work: Coskun 2022, Urva 2022 and Jastreboff 2023. This was checked on 14 October 2026. Their weight results were reported over weeks. Each is set out below with its study.
In the Phase 1 study of 45 healthy adults, a drop in body weight lasted up to day 43 after a single exposure. This early safety-study finding does not describe other people (Coskun et al., Cell Metabolism, 2022). In the 12-week Phase 1b study of 72 adults with type 2 diabetes, the placebo-adjusted weight loss reached up to 8.96 kg in the highest group. It is one small early-phase result. It does not describe other groups (Urva et al., The Lancet, 2022).
In the Phase 2 obesity trial of 338 adults, the highest arm averaged -17.5% at 24 weeks and -24.2% at 48 weeks. That is a result for that trial population. The developer funded the trial (Jastreboff et al., New England Journal of Medicine, 2023). An exit-interview study asked 40 adults with obesity about their experience. They came from the Phase 2 trial. The developer funded it. Of 36 people treated with retatrutide, 31 said their eating habits had changed. This was within the first 8 weeks. Interviews rely on memory. So that figure is a hint about timing, not a measurement (Goetz et al., Obesity Pillars, 2025). The study findings page sets out those results with their limits.
- GuideThe study findings pageWhat published retatrutide trials found on weight, body fat, appetite and side effects, which registered trials are running in Australia, and what the studies do not show.
How long does retatrutide last in the body?
In the 72-adult Phase 1b study in type 2 diabetes, retatrutide's half-life was approximately six days. So the measured amount fell by half about once a week in that group. It is a small early-phase result (Urva et al., The Lancet, 2022). In the Singapore study of 45 healthy adults, single half-lives ran from 104 to 225 hours. That was a small single-exposure result (Coskun et al., Cell Metabolism, 2022). None of the Coskun 2022, Urva 2022 and Carneiro 2026 papers reports a complete-clearance time (checked 14 October 2026). A 2026 analytical study looked at four adults who used retatrutide outside a trial. Intact retatrutide stayed detectable in plasma for about 56 days after the first exposure. None was found in urine. That is a detection result from four people and a method-checking design. It is not a clearance time (Carneiro et al., Rapid Communications in Mass Spectrometry, 2026).
A half-life is a statistical clock, not an expiry date. The amount keeps falling through each half-life. How long a trace shows up depends on the test. In the 2026 study of four adults who used retatrutide outside a trial, the limit of detection was 6.14 ng/mL in plasma. The abstract does not name the product source. So the detection window belongs to that method. It also belongs to those samples (Carneiro et al., Rapid Communications in Mass Spectrometry, 2026).
How long any effect lasts after treatment stops is a separate question from how long the molecule lasts. TRIUMPH-6 (NCT06859268) follows participants through an 80-week lead-in. Then it randomises them to continue retatrutide or switch to placebo. It lists primary completion as estimated for April 2028 (ClinicalTrials.gov, checked 14 October 2026).
- SourceNCT06859268
Does retatrutide exposure rise in step with the dose?
In the Phase 1 study of 45 healthy adults, total exposure rose nearly in step with the dose across six ascending groups. The developer funded this small study. It does not show the same pattern. This holds outside the range it covered (Coskun et al., Cell Metabolism, 2022). The 72-adult Phase 1b study in type 2 diabetes also reported exposure that rose in step with the dose. It was a small early-phase trial funded by the developer. It does not show the same pattern. This holds outside the groups it studied (Urva et al., The Lancet, 2022).
Predictable on average is not the same person to person. In the Phase 1 study of 45 healthy adults, total exposure varied by person. The coefficient of variation ran from 13% to 34%. It ran from 10% to 37% for peak level across the six groups. The coefficient of variation is the spread around the mean, shown as a percentage. So in that small study the same group gave quite different exposures in different people. A mean describes no single participant (Coskun et al., Cell Metabolism, 2022).
Why does retatrutide stay in the blood for days?
The paper that describes retatrutide's design links its long half-life to how the molecule is built. Retatrutide is a 39-amino-acid peptide on a GIP backbone. A C20 fatty diacid is attached through a linker at Lys17. That fatty-acid tail is a standard design for binding albumin. Albumin is the carrier protein in human blood. It makes up most of the protein there (Coskun et al., Cell Metabolism, 2022). The paper also lists three engineered changes: Aib2, αMeL13 and Aib20. They were made to make the peptide harder for the body to break down.
Your albumin has run a taxi service since long before anyone designed a peptide to hitch a ride. Fatty acids hop on, ride the blood, and hop off where they are needed. A fatty-acid tail lets a peptide buy a ticket on the same service. The paper presents that albumin binding as the design reason for the long half-life. It is a design reason, not a measurement in people (Coskun et al., Cell Metabolism, 2022).
One honest limit sits under the story. The Coskun et al. paper (Cell Metabolism, 2022), checked on 14 October 2026, does not tabulate a human free fraction, which is the share of the compound travelling unbound. It gives no percentage bound either. So this page does not supply one.
Is research-use retatrutide the same material the trials measured?
No. The human trial figures on this page were measured on the trial drug product. Enrolled participants got it under trial conditions. See Coskun et al., Cell Metabolism, 2022 and Urva et al., The Lancet, 2022. The one analytical study here looked at four adults using retatrutide outside a trial. It did not name its product source (Carneiro et al., Rapid Communications in Mass Spectrometry, 2026). Research-use reference material is a laboratory compound. The trial PK figures describe one investigational product studied in two Phase 1 trials. Research material is not a medicine. It is not a substitute for one. It is not for human or animal use. The trial figures describe what happened inside those trials. They say nothing about any material outside them.
Laboratory work uses reference material with paperwork. This site's retatrutide reference material listing is freeze-dried laboratory stock. Reading that paperwork is its own skill. It covers what a certificate records, what a third-party report proves and how a batch is traced. The quality and verification hub walks through it. The TGA safety alert of 14 September 2026 reported that retatrutide is in ongoing human trials. It is not approved by the TGA or a comparable international regulator.
Research use onlyRetatrutideIn stockretatrutide reference material
GuideThe quality and verification hubHow research peptides are tested and verified: purity methods, certificates of analysis, batch traceability, and what each document can and cannot tell you.- SourceTGA safety alert of 14 September 2026
Comparison
The studies behind the pharmacokinetic figures on this page: what each enrolled and measured, and where it is reported. This is a list of studies, not a table of results.
| Study | Registry number | Who was studied | What was measured | Where reported |
|---|---|---|---|---|
| Single-exposure Phase 1 | NCT03841630 | 45 healthy adults in Singapore, six ascending groups, 2019 | Half-life, time to peak, peak concentration and total exposure after a single exposure | Coskun et al., Cell Metabolism, 2022 |
| Repeated-exposure Phase 1b | NCT04143802 | 72 adults with type 2 diabetes in the United States, 2019 to 2020 | Half-life and dose proportionality over 12 weeks | Urva et al., The Lancet, 2022 |
| Kidney impairment trial | NCT05611957 | 29 participants, completed 5 September 2023 | Pharmacokinetics in kidney impairment; no results posted as of 14 October 2026 | ClinicalTrials.gov, checked 14 October 2026 |
| Liver impairment trial | NCT05916560 | 43 participants, completed 2 March 2025 | Pharmacokinetics in liver impairment; no results posted as of 14 October 2026 | ClinicalTrials.gov, checked 14 October 2026 |
| Analytical detection study | No registry number reported in the Carneiro 2026 abstract checked on 14 October 2026 | Four adults using retatrutide outside a trial | Intact retatrutide in plasma and urine by mass spectrometry; a detection method, not a clearance time | Carneiro et al., Rapid Communications in Mass Spectrometry, 2026 |
- SourceNCT03841630
- SourceNCT04143802
- SourceNCT05611957
- SourceNCT05916560
FAQ
What is retatrutide's half-life?
In a small Phase 1b study of 72 adults with type 2 diabetes, the half-life was about six days. The developer funded it. That figure is for that study population only (Urva et al., The Lancet, 2022). A small Phase 1 study of 45 healthy adults was funded by the developer. In it, group-average half-lives spanned 134 to 165 hours across six groups. That figure is for those participants only (Coskun et al., Cell Metabolism, 2022).
How long does retatrutide stay in the blood?
In the Phase 1 study of 45 healthy adults the group-average half-lives were 134–165 hours, about 5.6 to 6.9 days. So the level fell by half roughly once a week. This was in that small single-exposure group (Coskun et al., Cell Metabolism, 2022). None of the Coskun 2022, Urva 2022 and Carneiro 2026 papers reports a complete-clearance time (checked 14 October 2026).
How long does retatrutide take to reach peak concentration?
In the Phase 1 study of 45 healthy adults the group-median time to peak level fell between 12 and 72 hours after a single exposure. The median fell as the group's level rose. The result describes that small study only (Coskun et al., Cell Metabolism, 2022).
Is retatrutide dose-proportional?
After a single exposure, total exposure rose nearly in step with the dose across six groups of 45 healthy adults. That holds within the range the study covered (Coskun et al., Cell Metabolism, 2022). The repeated-exposure study of 72 adults with type 2 diabetes also reported a rise in exposure. The rise was in step with the dose. It was a small early-phase trial (Urva et al., The Lancet, 2022).
How long does retatrutide take to kick in?
In a small Phase 1 study of 45 healthy adults, the group-median time to peak retatrutide level ranged from 12 to 72 hours after a single exposure. That result is for that study only (Coskun et al., Cell Metabolism, 2022). Weight changes were measured over weeks and months. One example is -17.5% at 24 weeks in the highest arm of the Phase 2 obesity trial of 338 adults. That result is for that trial population only (Jastreboff et al., NEJM, 2023). None of these papers says when retatrutide starts to work: Coskun 2022, Urva 2022 and Jastreboff 2023. This was checked on 14 October 2026.
How long does retatrutide last?
The half-life was about six days in 72 adults with type 2 diabetes. That was a small early-phase trial (Urva et al., The Lancet, 2022). None of the Coskun 2022, Urva 2022 and Carneiro 2026 papers reports a complete-clearance time (checked 14 October 2026). A 2026 analytical study looked at four adults using retatrutide outside a trial. Intact retatrutide was found in plasma for about 56 days after the first exposure. That is a detection result, not a clearance time (Carneiro et al., Rapid Communications in Mass Spectrometry, 2026).
More in this hub
- GuideRetatrutideRetatrutide research hub: what the compound is, which receptor systems the literature maps it to, what the published trials measured, and how it compares with approved medicines.
- GuideRetatrutide vs Mounjaro vs Ozempic: what's the difference?Retatrutide, Mounjaro, and Ozempic compared by molecule, receptor systems, and approval status. Research material is not a medicine.
- GuideWhat is the difference between GLP-1 and GLP-3?GLP-1 is a natural gut hormone. GLP-3 is a nickname. Learn what GLP-1, GIP and glucagon receptors mean, and what names alone cannot show.
- GuideIs retatrutide available in the USA? What the public record saysRetatrutide's US approval record, checked 17 October 2026. Read FDA statements and Lilly's filing plan. A trial listing does not mean medicine approval.
- GuideHow much does retatrutide cost? Is there an approved price?The checked records give no price for retatrutide as an approved medicine. Learn what approval, a maker's price and a PBS listing each mean.
- GuideWhat does retatrutide do in the body? The three receptors in the papersRetatrutide papers name three cell receivers: GIP, GLP-1 and glucagon receptors. Learn what cell tests and human trials measure, and what each cannot show.
- GuideHow are people getting retatrutide? Trials, approval and research supplyWhat trial records and medicine checks say about retatrutide access and research-only labels. Dated facts, without buying or personal-use advice.
- GuideWho should not take retatrutide? What the trial exclusion lists sayWho was left out of retatrutide trials? Read how TRIUMPH entry rules differ and why these lists cannot show personal safety.
- GuideWhat makes a peptide company reputable? How to check a supplier's testingCheck a peptide supplier's batch records and test reports. Learn what purity tests, mass tests and outside labs can show.
- GuideWhat is replacing tirzepatide? Weight-loss medicines in Phase 3 in 2026A dated look at retatrutide, CagriSema, survodutide and VK2735. Read about their targets, Phase 3 studies and what the records cannot show.
- GuideRetatrutide and type 2 diabetes: what the trials measuredWhat retatrutide diabetes trials measured. Read about HbA1c, the Lancet Phase 2 paper and TRANSCEND-T2D study plans. Check dated study records and limits.
- GuideHow long has retatrutide been studied?Retatrutide's research record from the first dated human enrollment in December 2019 to Phase 3 in 2026. Research material is not a medicine.
- GuideRetatrutide Phase 2 trial: what did the paper find?A guided read of the retatrutide Phase 2 obesity trial (NEJM 2023): 338 adults, 48 weeks, and what the primary end point actually measured.
- GuideWhat is the molecular formula of retatrutide?Retatrutide molecular formula: C221H342N46O68, the registry record it comes from, and what a count of atoms cannot prove. Research use only.
- GuideNCT05882045: what is the TRIUMPH-3 retatrutide trial?NCT05882045 is TRIUMPH-3, a Phase 3 retatrutide trial in obesity with cardiovascular disease. Registry status, enrolment, endpoint, and no posted results.
- GuideNCT05929066: what is the TRIUMPH-1 retatrutide trial?NCT05929066 is TRIUMPH-1, a Phase 3 retatrutide trial in obesity without type 2 diabetes. Registry status, enrolment, nested sub-studies, no posted results.
- GuideWhere does tirzepatide come from? Lilly's LY3298176Tirzepatide began as Eli Lilly's LY3298176, a synthetic 39-amino-acid peptide engineered on a GIP backbone. Whether it is a peptide or a hormone, and how it differs from semaglutide.
- GuideSURPASS and SURMOUNT: what the tirzepatide trials measuredSURPASS trials measured HbA1c in type 2 diabetes. SURMOUNT trials measured body weight. Two named tirzepatide programmes, two different questions.
- GuideRetatrutide in Australia: is it legal, approved or available yet?Retatrutide's approval and legal status in Australia and the US as of 14 October 2026: TGA statements, the Poisons Standard, the WADA list, the developer's submission plan, trial records and what is still unknown.
- GuideRetatrutide study findings: what do the clinical trials show?What published retatrutide trials found on weight, body fat, appetite and side effects, which registered trials are running in Australia, and what the studies do not show.
- GuideRetatrutide side effects: what trials and regulators have recordedThe side effects recorded in retatrutide trials, how often they occurred against placebo, serious events, and what Australian authorities have reported about products sold as retatrutide.
Citations
6 sourcesCoskun T et al. Cell Metabolism. 2022;34(9):1234-1247.e9.
doi:10.1016/j.cmet.2022.07.013Urva S et al. The Lancet. 2022;400(10366):1869-1881.
doi:10.1016/S0140-6736(22)02033-5Urva S et al. Diabetes, Obesity and Metabolism. 2023.
doi:10.1111/dom.15167- Sourcedoi:10.1111/dom.15167
Jastreboff AM et al. New England Journal of Medicine. 2023;389(6):514-526.
doi:10.1056/NEJMoa2301972Goetz IA et al. Obesity Pillars. 2025;16:100220.
doi:10.1016/j.obpill.2025.100220Carneiro GRA et al. Rapid Communications in Mass Spectrometry. 2026;40(23):e70179.
doi:10.1002/rcm.70179- Sourcedoi:10.1002/rcm.70179
Continue
Retatrutide reference materialResearch use only, not for human or animal use.
Read the retatrutide research guideForm Laboratories supplies research-use-only reference material. This article is an educational summary of published third-party literature. It is not medical advice, not a use instruction, and research material is not for human or animal use.
